Loading clinical trials...

NOT_YET_RECRUITINGNA

The Impact of Improved Vagal Function on Periaqueductal Gray Connectivity

NCT05618067•Virginia Commonwealth University

Summary

This study is being to see if participating in breathing exercise training and practicing this training will help with Postural tachycardia syndrome (POTS). The information may help doctors to learn more about how the different parts of people's brains communicate.

Eligibility

Age

18 - 50 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age 18-50 years
•Diagnosis of POTS, orthostatic intolerance (with or without syncope), syncope, or near-syncope
•Can speak and read in English
•Upcoming new patient VCU Comprehensive Autonomics Center clinic visit scheduled at least 1 week in the future

Exclusion Criteria

•Inflammatory arthritis, connective tissue or auto-immune disorder
•Any chronic neurological disorder besides POTS, orthostatic intolerance (with or without syncope), syncope, or near-syncope
•Patients who have already had a new patient clinic visit where they were exposed to breathing exercise education
•Evidence of unstable medical disorder, such as kidney (rising creatinine, or end-stage renal failure) or liver impairment (rising AST or ALT, or end-stage with coagulopathy), poorly controlled significant cardiovascular (CHF), respiratory, endocrine (diabetes - A1c \> 9 - or untreated thyroid dysfunction) or uncontrolled psychiatric illness (such as untreated depression, psychosis, etc.)
•Neuropathy, central nervous system disorder (e.g., Cerebral palsy, developmental delay, seizure disorder, MS, stroke, etc.)
•Treatment with a drug or medical device within the previous 30 days that has not received regulatory approval
•Use of hormones (except insulin, thyroid replacement or oral contraceptives, which will be carefully documented)
•Current substance or alcohol abuse
•Any major surgical intervention with general anesthesia in the last 60 days and minor procedure, such as tooth extraction, endoscopy, etc., with local or conscious sedation within 7 days
•Any on-going or pending medical, health or disability related litigation, or current pursuit of disability
+4 more criteria

Locations (1)

Virnigia Commonwealth University

Richmond, Virginia, United States

Key Dates

Start Date

April 1, 2026

Primary Completion Date

December 1, 2028

Completion Date

December 1, 2028

Last Updated

February 18, 2026

Enrollment

ESTIMATED participants

Conditions

Postural Tachycardia Syndrome

Interventions

breathing exercise training

BEHAVIORAL

Contacts

Thomas Chelimsky, M.D.

CONTACT

(804)-628-0145 thomas.chelimsky@vcuhealth.org

Madison Maxwell, B.S.

CONTACT

maxwellme@vcu.edu

Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome

NCT05421208

Post-acute COVID-19 SyndromePostural Tachycardia Syndrome (POTS)+2 more

View study

RECRUITINGNA

Hypercapnia and Orthostatic Tolerance in Postural Orthostatic Tachycardia Syndrome

NCT04271878

Postural Tachycardia SyndromeOrthostatic Intolerance

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 18, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Impact of Improved Vagal Function on Periaqueductal Gray Connectivity

Inclusion Criteria

Exclusion Criteria

Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome

Hypercapnia and Orthostatic Tolerance in Postural Orthostatic Tachycardia Syndrome

Sleep Actigraphy in Postural Tachycardia Syndrome (POTS)

Autonomic Determinants of POTS - Pilot 2

Phenotyping Mitochondrial and Immune Dysfunction in POTS With Targeted Clinical Intervention.

Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS)